18 Result(s)

Article

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the be...

Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot… in Nature Medicine (2024)

Article

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results fro...

Hermann Einsele, Philippe Moreau, Nizar Bahlis, Manisha Bhutani… in Advances in Therapy (2024)

Article

Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Teclistamab is the first approved B cell maturation antigen × CD3 bispecific antibody with precision dosing for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). We compa...

Philippe Moreau, María-Victoria Mateos, Maria Esther Gonzalez Garcia… in Advances in Therapy (2024)

Article

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions

Anaïs Schavgoulidze, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu… in Blood Cancer Journal (2023)

Article

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from frontline regimens that include novel agents. Thi...

Enrique M. Ocio, Aurore Perrot, Pierre Bories, Jesus F. San-Miguel… in Leukemia (2023)

Article

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)

This round table discussion organized by the International Academy for Clinical Hematology (IACH) was dedicated to the 19th annual meeting of the International Myeloma Society (IMS), which was held in Los Ange...

Nizar J. Bahlis, Luciano J. Costa, Thierry Facon… in Clinical Hematology International (2023)

Article

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

Patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE-RRMM) have a poor prognosis and limited treatment options. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, was s...

Philippe Moreau, Niels W. C. J. van de Donk, Michel Delforge… in Advances in Therapy (2023)

Article

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)

Despite the implementation of new therapeutic agents, management of relapsed multiple myeloma (MM) remains a challenge. Salvage autologous hematopoietic cell transplant (AHCT) remains a valid therapeutic optio...

Zoe van de Wyngaert, Florent Malard, Cyrille Hulin… in Clinical Hematology International (2023)

Article

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry

Somayya Noori, Charissa Wijnands, Pieter Langerhorst… in Blood Cancer Journal (2023)

Article

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

CD38 is a transmembrane glycoprotein that functions both as a receptor and an ectoenzyme, playing key roles in the regulation of calcium signaling and migration of immune cells to tumor microenvironments. High...

Xavier Leleu, Thomas Martin, Katja Weisel, Fredrik Schjesvold… in Annals of Hematology (2022)

Article

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal anti...

Maria-Victoria Mateos, Katja Weisel, Valerio De Stefano, Hartmut Goldschmidt… in Leukemia (2022)

Article

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Joseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent… in Blood Cancer Journal (2021)

Article

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

Maroulio Pertesi, Maxime Vallée, **aomu Wei, Maria V. Revuelta, Perrine Galia… in Leukemia (2019)

Article

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors f...

Charles Dumontet, Cyrille Hulin, Meletios A. Dimopoulos, Andrew Belch… in Leukemia (2018)